MX2020007237A - Combined therapy and prophylaxis for genital tract infections. - Google Patents

Combined therapy and prophylaxis for genital tract infections.

Info

Publication number
MX2020007237A
MX2020007237A MX2020007237A MX2020007237A MX2020007237A MX 2020007237 A MX2020007237 A MX 2020007237A MX 2020007237 A MX2020007237 A MX 2020007237A MX 2020007237 A MX2020007237 A MX 2020007237A MX 2020007237 A MX2020007237 A MX 2020007237A
Authority
MX
Mexico
Prior art keywords
genital tract
tract infections
prophylaxis
combined therapy
gonorrhoeae
Prior art date
Application number
MX2020007237A
Other languages
Spanish (es)
Inventor
Michael W Russell
Yingru Liu
Nejat K Egilmez
Original Assignee
The Research Foundation Of The State Univ Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/824,700 external-priority patent/US20180071379A1/en
Priority claimed from US16/138,526 external-priority patent/US20190008941A1/en
Application filed by The Research Foundation Of The State Univ Of New York filed Critical The Research Foundation Of The State Univ Of New York
Publication of MX2020007237A publication Critical patent/MX2020007237A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12

Abstract

Provided is a method for treating and reducing the recurrence of genital tract infections such as gonococcal infections. The method comprises local application of IL-12 incorporated in polymeric microspheres. A method is also provided to reduce the incidence of genital tract infections caused by N. gonorrhoeae by administration of outer membrane vesicle preparations from N. gonorrhoeae and IL-12 incorporated in polymeric microspheres.
MX2020007237A 2017-11-28 2018-11-27 Combined therapy and prophylaxis for genital tract infections. MX2020007237A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/824,700 US20180071379A1 (en) 2012-05-29 2017-11-28 Combined therapy and prophylaxis for genital tract infections
US16/138,526 US20190008941A1 (en) 2012-05-29 2018-09-21 Combined therapy and prophylaxis for genital tract infections
PCT/US2018/062590 WO2019108528A1 (en) 2017-11-28 2018-11-27 Combined therapy and prophylaxis for genital tract infections

Publications (1)

Publication Number Publication Date
MX2020007237A true MX2020007237A (en) 2020-09-25

Family

ID=66665780

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007237A MX2020007237A (en) 2017-11-28 2018-11-27 Combined therapy and prophylaxis for genital tract infections.

Country Status (7)

Country Link
EP (1) EP3716995A4 (en)
JP (1) JP2021504478A (en)
CN (1) CN111698998A (en)
AU (1) AU2018375133A1 (en)
CA (1) CA3083741A1 (en)
MX (1) MX2020007237A (en)
WO (1) WO2019108528A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0107679B8 (en) * 2000-01-17 2021-05-25 Chiron Spa composition comprising Neisseria meningitidis serum group b outer membrane vesicles and an inorganic component and use thereof
US7892567B2 (en) * 2007-10-01 2011-02-22 Board Of Regents, The University Of Texas System Methods and compositions for immunization against chlamydial infection and disease
US9827319B2 (en) * 2012-05-29 2017-11-28 The Research Foundation For The State University Of New York Combined therapy and prophylaxis for genital tract infections

Also Published As

Publication number Publication date
JP2021504478A (en) 2021-02-15
CN111698998A (en) 2020-09-22
WO2019108528A1 (en) 2019-06-06
EP3716995A1 (en) 2020-10-07
EP3716995A4 (en) 2021-08-25
CA3083741A1 (en) 2019-06-19
AU2018375133A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
NZ728072A (en) Modulators of toll-like receptors for the treatment of hiv
MX2016011132A (en) Methods for treating skin infection by administering an il-4r antagonist.
IN2013MU00711A (en)
MX2018012719A (en) Use of gram negative species to treat atopic dermatitis.
MX2020000467A (en) Immunomodulatory retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy.
IN2013MU03583A (en)
PH12019502316A1 (en) Combination cancer immunotheraphy with pentaaza macrocyclic ring complex
MX2020011295A (en) Treatment of atopic dermatitis.
MX2019004973A (en) Ror-gamma modulators.
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX2019012757A (en) Orally administrable enzalutamide-containing pharmaceutical composition.
MX2020000009A (en) Novel secnidazole soft gelatin capsule formulations and uses thereof.
CA3011003A1 (en) Bacterial ghosts for the treatment of cancer
MX2020007237A (en) Combined therapy and prophylaxis for genital tract infections.
EA201992431A1 (en) COMBINED CANCER IMMUNOTHERAPY USING PENTA-ASA-MACROCYCLIC RING COMPLEX
MX2019004591A (en) Immunosuppressive treatments, formulations and methods.
ZA202104786B (en) Deutetrabenazine for the treatment of dyskinesia in cerebral palsy
MX2021004138A (en) Methods and formulations for treating chemotherapy-induced nausea and vomiting.
WO2019075168A3 (en) Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
WO2018062876A3 (en) Kit for treatment of osteoarthritis to reduce pain
MX2018006882A (en) Vaginal inserted estradiol pharmaceutical compositions and methods.
MX2018015240A (en) Compositions comprising timolol and their use in the treatment of rosacea by topical administration.
UA115642C2 (en) METHOD OF TREATMENT OF ACUTE DISEASE IN THE STAGE OF EXTRACTION COMBINED WITH INTESTINAL DYSBIOSIS
WO2019035143A3 (en) Medicated honey and method of preparation thereof
CO2018001531A2 (en) Lisobactin for use in the treatment of bovine mastitis